Market Overview

Second Top Firm Downgrades Colgate-Palmolive In Two Months

Share:
Related CL
The Top 10 Value Stocks In The S&P 500
Colgate-Palmolive Set To Outperform In 2018, According To Macquarie
Stocks To Watch: Earnings Season Hits Higher Gear (Seeking Alpha)
Related PG
The Top 10 Value Stocks In The S&P 500
Upcoming Netflix Earnings: Subscriber Growth And Price Hikes In Focus
Stocks To Watch: Earnings Season Hits Higher Gear (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst Dara Mohsenian downgraded the rating on Colgate-Palmolive Company (NYSE: CL) from Overweight to Equal-Weight, while reducing the price target from $76 to $72.

Colgate-Palmolive's stock is currently trading at a premium versus the company's mega-cap peers. Analyst Dara Mohsenian believes that the valuation "appropriately reflects the company's superior fundamentals, including greater exposure to higher-growth emerging market geographies and personal care product categories, a superior ROIC, a more defensive business mix, and greater pricing power."

On April 20, Goldman Sachs had downgraded the rating on Colgate-Palmolive from Neutral to Sell, while reducing the price target from $71 to $64, saying that investors seemed to be underestimating the company's FX exposure and the concomitant impact on its margins.

Colgate-Palmolive is expected to generate higher top line growth than its peers, given its 5.4 percent two-year average organic sales growth over the last three quarters. As compared to the 3 percent growth rate achieved by Procter & Gamble Co (NYSE: PG), The Coca-Cola Co (NYSE: KO) and PepsiCo, Inc. (NYSE: PEP).

In the report Morgan Stanley noted, "Near term, pricing power is a key industry theme given US-based companies' desire to pass on pricing internationally to cover unfavorable FX, as well as hold on to US pricing despite lower commodity prices. We believe CL's pricing power remains greater than peers given its skew to the oral/personal care categories, which have more brand loyalty and less trade-down risk given limited private label penetration."

The EPS estimates for 2015, 2016 and 2017 have been reduced from $2.90 to $2.88, from $3.18 to $3.13 and from $3.47 to $3.41, respectively, to reflect the continued unfavorable FX pressure as well as a difficult competitive environment.

Latest Ratings for CL

DateFirmActionFromTo
Dec 2017MacquarieUpgradesNeutralOutperform
Dec 2017Deutsche BankInitiates Coverage OnHold
Nov 2017Societe GeneraleDowngradesHoldSell

View More Analyst Ratings for CL
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Price Target Analyst Ratings

 

Related Articles (CL + KO)

View Comments and Join the Discussion!